On 23 Oct 2023, the clinical results of Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1% was reported at the ESMO Congress.

Sirius Therapeutics reports its application to initiate the primary clinical testing of Factor XI siRNA, an advanced, long-lasting anticoagulant for blood clot issues.

This article summarized the latest R&D progress of Sulfamethazine, the Mechanism of Action for Sulfamethazine, and the drug target R&D trends for Sulfamethazine.

Trishula Therapeutics kickstarts Phase 2 study of TTX-030, a compound directed against CD39, in initial treatment of patients with advanced pancreatic cancer.

The clinical trial for Capmatinib Hydrochloride took center stage at the 2023 ESMO Congress, demonstrating its potential to treat aNSCLC.

Apart from the approved ADCs, there are hundreds of ADCs under clinical investigation, covering a increasingly diverse range of targets.

Phase III EMERALD-1 trial reveals Imfinzi combined with bevacizumab achieved primary objective by improving progression-free survival in advanced liver cancer patients who qualify for embolisation.

This article summarized the latest R&D progress of Sulodexide, the Mechanism of Action for Sulodexide, and the drug target R&D trends for Sulodexide.

Eccogene acquires unique licensing rights from AstraZeneca to advance and market ECC5004, a small molecule GLP-1 receptor agonist, for cardiovascular metabolic conditions.

Atezolizumab plus bevacizumab (AB) is a frequent first-line treatment for advanced hepatocellular carcinoma (HCC), shown superior to sorafenib in the IMbrave150 trial. On October 20, 2023, an Atezolizumab trial was presented at the ESMO Congress.

Allgenesis reports promising initial safety and effectiveness results for AG-73305 phase 2a trial tackling Diabetic Macular Edema, presented at the American Academy of Ophthalmology.

This article summarized the latest R&D progress of TBO-Filgrastim, the Mechanism of Action for TBO-Filgrastim, and the drug target R&D trends for TBO-Filgrastim.